<![CDATA[Every year in the United States, flu complications among elderly adults cost a staggering $56 billion. Adults who are 65 and older, including PACE participants, are at a higher risk for encountering complications from the flu virus. This is especially true for those with underlying health conditions. The enormous clinical and economic burden from influenza outbreaks has long motivated vaccine manufacturers to invest in developing an improved annual flu vaccine for senior adults. One vaccine, licensed in the United States in 2009, and known as the trivalent inactivated influenza vaccine Fluzone High-Dose, has demonstrated better efficacy and effectiveness compared with standard-dose influenza vaccines in older adults. [Tweet “Is the high-dose #fluvaccine really better for #PACE participants?”]
Is the High-dose Flu Vaccine Effective for PACE Participants?
A randomized, controlled FIM12 study proved the overall effectiveness of the high-dose flu vaccine. In this study, 31,989 participants were enrolled from 126 research centers in Canada and the United States.
According to this study, among those 65 years or older, Fluzone High-Dose provided better protection and induced significantly higher antibody responses against laboratory-confirmed influenza than Fluzone Standard-Dose.
Investigators from the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services, and the U.S. Food and Drug Administration reported that the high-dose vaccine was 22 percent more effective than the standard-dose vaccine for the prevention of probable influenza.
It was also 22 percent more effective in preventing flu-related emergency room visits and hospital admissions, both important factors among PACE participants.
What About the Cost of the High-dose Flu Vaccine for PACE Participants?
A critical health question for senior adults—and PACE centers—is the cost-effectiveness of the high-dose flu vaccine. Could the vaccine reduce the significant economic burden of flu outbreaks in adults older than age 65?
In one study of cost analysis, the high-dose trivalent inactivated flu vaccine is a cost-saving alternative to the standard-dose vaccine. Moreover, the additional cost of administering a high-dose instead of a standard-dose vaccine produced a staggering 587 percent financial benefit to the healthcare system.
The majority of those savings came through reductions in cardiorespiratory hospital admissions related to the flu. The study results indicate that the high-dose vaccine saved costs over the analyzed two-year period, and therefore showed better cost-effectiveness than most other strategies used.
Although initial costs for the high-dose flu vaccine are higher than the standard-dose vaccine, results of cost analyses favor the high-dose vaccine, mainly because of the reduction of hospital admissions.
PACE providers must focus on patient-centered care while considering the well-being of the participant and the cost savings when recommending immunizations during flu season.
Seniors, including PACE participants, have unique and specialized needs. Our Grane Rx team of geriatric-specialized pharmacists understands those challenges and works with PACE centers to overcome them. Partner with us today by calling (412) 449-0504.]]>